CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 315 enrolled
Drug / intervention
Sodium risedronatedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02106455
NCT02106455N/ACompleted
CompareCT.gov

Sodium Risedronate 17.5 mg Tablets Special Drug Use Surveillance in Patients With Osseous Paget's Disease (All-case Surveillance) - 48-week Surveillance -

Takeda·observational·Posted Apr 8, 2014·Updated Jun 3, 2019

In Brief

An observational study evaluating Sodium risedronate for Osseous Paget's Disease. Completed, enrolled 315 participants across 2 sites.

Detailed Summary

The purpose of this study is to evaluate the safety and efficacy of sodium risedronate tablets administered once daily (one tablet per dose) in patients with osseous Paget's disease for 48 weeks from baseline in daily medical practice.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsOsseous Paget's Disease
CountriesJapan
Collaborators--

Timeline

N/ACompletedFinished
2009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 8, 2014
Enrollment StartAug 1, 2008
Primary CompletionOct 24, 2017
TodayJul 2, 2026
Enrollment to primary: 9.2 yearsPosted 12.2 years ago

Interventions

Sodium risedronatedrug

Sodium risedronate tablets